Agonism and antagonism at the insulin receptor.
Insulin can trigger metabolic as well as mitogenic effects, the latter being pharmaceutically undesirable. An understanding of the structure/function relationships between insulin receptor (IR) binding and mitogenic/metabolic signalling would greatly facilitate the preclinical development of new ins...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3531387?pdf=render |
id |
doaj-77029b21ff594f02ba9f32822e1fa7cc |
---|---|
record_format |
Article |
spelling |
doaj-77029b21ff594f02ba9f32822e1fa7cc2020-11-25T01:57:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01712e5197210.1371/journal.pone.0051972Agonism and antagonism at the insulin receptor.Louise KnudsenBo Falck HansenPia JensenThomas Åskov PedersenKirsten VestergaardLauge SchäfferBlagoy BlagoevMartin B OleksiewiczVladislav V KiselyovPierre De MeytsInsulin can trigger metabolic as well as mitogenic effects, the latter being pharmaceutically undesirable. An understanding of the structure/function relationships between insulin receptor (IR) binding and mitogenic/metabolic signalling would greatly facilitate the preclinical development of new insulin analogues. The occurrence of ligand agonism and antagonism is well described for G protein-coupled receptors (GPCRs) and other receptors but in general, with the exception of antibodies, not for receptor tyrosine kinases (RTKs). In the case of the IR, no natural ligand or insulin analogue has been shown to exhibit antagonistic properties, with the exception of a crosslinked insulin dimer (B29-B'29). However, synthetic monomeric or dimeric peptides targeting sites 1 or 2 of the IR were shown to be either agonists or antagonists. We found here that the S961 peptide, previously described to be an IR antagonist, exhibited partial agonistic effects in the 1-10 nM range, showing altogether a bell-shaped dose-response curve. Intriguingly, the agonistic effects of S961 were seen only on mitogenic endpoints ((3)H-thymidine incorporation), and not on metabolic endpoints ((14)C-glucose incorporation in adipocytes and muscle cells). The agonistic effects of S961 were observed in 3 independent cell lines, with complete concordance between mitogenicity ((3)H-thymidine incorporation) and phosphorylation of the IR and Akt. Together with the B29-B'29 crosslinked dimer, S961 is a rare example of a mixed agonist/antagonist for the human IR. A plausible mechanistic explanation based on the bivalent crosslinking model of IR activation is proposed.http://europepmc.org/articles/PMC3531387?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Louise Knudsen Bo Falck Hansen Pia Jensen Thomas Åskov Pedersen Kirsten Vestergaard Lauge Schäffer Blagoy Blagoev Martin B Oleksiewicz Vladislav V Kiselyov Pierre De Meyts |
spellingShingle |
Louise Knudsen Bo Falck Hansen Pia Jensen Thomas Åskov Pedersen Kirsten Vestergaard Lauge Schäffer Blagoy Blagoev Martin B Oleksiewicz Vladislav V Kiselyov Pierre De Meyts Agonism and antagonism at the insulin receptor. PLoS ONE |
author_facet |
Louise Knudsen Bo Falck Hansen Pia Jensen Thomas Åskov Pedersen Kirsten Vestergaard Lauge Schäffer Blagoy Blagoev Martin B Oleksiewicz Vladislav V Kiselyov Pierre De Meyts |
author_sort |
Louise Knudsen |
title |
Agonism and antagonism at the insulin receptor. |
title_short |
Agonism and antagonism at the insulin receptor. |
title_full |
Agonism and antagonism at the insulin receptor. |
title_fullStr |
Agonism and antagonism at the insulin receptor. |
title_full_unstemmed |
Agonism and antagonism at the insulin receptor. |
title_sort |
agonism and antagonism at the insulin receptor. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
Insulin can trigger metabolic as well as mitogenic effects, the latter being pharmaceutically undesirable. An understanding of the structure/function relationships between insulin receptor (IR) binding and mitogenic/metabolic signalling would greatly facilitate the preclinical development of new insulin analogues. The occurrence of ligand agonism and antagonism is well described for G protein-coupled receptors (GPCRs) and other receptors but in general, with the exception of antibodies, not for receptor tyrosine kinases (RTKs). In the case of the IR, no natural ligand or insulin analogue has been shown to exhibit antagonistic properties, with the exception of a crosslinked insulin dimer (B29-B'29). However, synthetic monomeric or dimeric peptides targeting sites 1 or 2 of the IR were shown to be either agonists or antagonists. We found here that the S961 peptide, previously described to be an IR antagonist, exhibited partial agonistic effects in the 1-10 nM range, showing altogether a bell-shaped dose-response curve. Intriguingly, the agonistic effects of S961 were seen only on mitogenic endpoints ((3)H-thymidine incorporation), and not on metabolic endpoints ((14)C-glucose incorporation in adipocytes and muscle cells). The agonistic effects of S961 were observed in 3 independent cell lines, with complete concordance between mitogenicity ((3)H-thymidine incorporation) and phosphorylation of the IR and Akt. Together with the B29-B'29 crosslinked dimer, S961 is a rare example of a mixed agonist/antagonist for the human IR. A plausible mechanistic explanation based on the bivalent crosslinking model of IR activation is proposed. |
url |
http://europepmc.org/articles/PMC3531387?pdf=render |
work_keys_str_mv |
AT louiseknudsen agonismandantagonismattheinsulinreceptor AT bofalckhansen agonismandantagonismattheinsulinreceptor AT piajensen agonismandantagonismattheinsulinreceptor AT thomasaskovpedersen agonismandantagonismattheinsulinreceptor AT kirstenvestergaard agonismandantagonismattheinsulinreceptor AT laugeschaffer agonismandantagonismattheinsulinreceptor AT blagoyblagoev agonismandantagonismattheinsulinreceptor AT martinboleksiewicz agonismandantagonismattheinsulinreceptor AT vladislavvkiselyov agonismandantagonismattheinsulinreceptor AT pierredemeyts agonismandantagonismattheinsulinreceptor |
_version_ |
1724975293196664832 |